Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Short-term Investments: 2016-2025

Historic Short-term Investments for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $222.7 million.

  • Ultragenyx Pharmaceutical's Short-term Investments fell 52.71% to $222.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.7 million, marking a year-over-year decrease of 52.71%. This contributed to the annual value of $436.3 million for FY2024, which is 19.99% up from last year.
  • Ultragenyx Pharmaceutical's Short-term Investments amounted to $222.7 million in Q3 2025, which was down 28.44% from $311.3 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Short-term Investments' 5-year high stood at $614.8 million during Q4 2022, with a 5-year trough of $222.7 million in Q3 2025.
  • In the last 3 years, Ultragenyx Pharmaceutical's Short-term Investments had a median value of $367.4 million in 2025 and averaged $374.4 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first soared by 59.31% in 2021, then crashed by 52.71% in 2025.
  • Ultragenyx Pharmaceutical's Short-term Investments (Quarterly) stood at $432.6 million in 2021, then skyrocketed by 42.12% to $614.8 million in 2022, then plummeted by 40.86% to $363.6 million in 2023, then rose by 19.99% to $436.3 million in 2024, then slumped by 52.71% to $222.7 million in 2025.
  • Its Short-term Investments was $222.7 million in Q3 2025, compared to $311.3 million in Q2 2025 and $367.4 million in Q1 2025.